Thinking Out Loud (Blog)
PANDA: The Newest Product at EpiVax
EpiVax has been awarded a $1 million contract from the Food and Drug Administration (FDA) to demonstrate and validate the best practices and procedures for assessing generic peptide drugs and related impurities for immunogenic potential.
read more
Interview with Brian Roberts: Protein Therapeutics Manager
One-on-One Interview with Brian Roberts: Protein Therapeutics Manager at EpiVax We recently sat down with our very own Protein Therapeutics Manager, Brian Roberts, to discuss his ongoing work with PANDA. In this exclusive interview, he shares what his job entails and...
read more
Bamako, not Timbuktu
The beginning, and why we go : A look back at to February 2003, trip to Bamako A Travelogue by Annie De Groot, M.D. Dr. Annie De Groot and her associate Julie McMurry traveled to Bamako, Mali in January in 2003 to visit an AIDS vaccine clinical trial site. In 2002,...
read more
Let’s get physical – (Biophysical properties of Mabs)
Hello, protein therapeutics developers! We're presenting some work in Montpellier at the Antibody Industrial Symposium (AIS) and we thought we'd share in advance of the presentation. Why? Because we thought you would want to know that Tregitope content is more...
read more
EpiVax and GAIA Vaccine Foundation Celebrate Women’s Achievements Throughout History and Across Nations
PROVIDENCE, R.I., March 9, 2018 /PRNewswire/ -- EpiVax Inc., ("EpiVax") an innovative Rhode Island-based biotechnology company, has a lot to celebrate on International Women's Day. The company, founded and led by Dr. Annie De Groot, boasts a female-majority work force...
read more
Immune Engineering Cas9: Yes We Can!
The CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-associated nuclease-9) system has been a model of great promise in the gene therapy research community since 2012. It was initially discovered as the adaptive immune system of certain...
read more